Carl Icahn says new Illumina CEO has his ‘full support’ months after proxy fight

Carl Icahn says new Illumina CEO has his ‘full support’ months after proxy fight


Carl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.

David A. Grogan | CNBC

Carl Icahn on Thursday expressed his support for Illumina‘s new CEO Jacob Thaysen – a relief for the company as it tries to rebound from a bitter proxy fight with the billionaire activist investor. 

“I think he will do an excellent job and he has my full support,” Icahn said in a post on X, noting that he spoke with Thaysen. 

Icahn, who continues to own a small stake in Illumina, launched a proxy battle over the company’s decision to close its $7.1 billion acquisition of cancer test developer Grail in 2021 without approval from antitrust regulators in U.S. and European Union. 

Icahn was a staunch critic of Illumina’s former CEO Francis deSouza, who ultimately resigned after the proxy battle in May despite securing enough votes to stay. 

“I’d find it comical, if it wasn’t so reprehensible that ILMN’s share price is down 63% due to CEO Francis deSouza making such an absurd and questionable purchase,” Icahn said in a statement to CNBC in March.

Jacob Thaysen

Source: Illumina

Shares of Illumina are now down nearly 70% since closing the Grail deal in August 2021. The company’s market value has fallen to roughly $25 billion from around $75 billion in August 2021.

Investors will be watching to see how Thaysen approaches the Grail business, and whether he can rebuild the market value the company lost.

Thaysen will step in as Illumina’s CEO on Sept. 25 after nearly a decade at medical devices firm Agilent Technologies, where he ran its largest analytical-lab unit, and doubled the division’s operating profit.





Source

Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says
Health

Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says

The CEO of Novartis said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build a “unique position.” Speaking to CNBC, Vas Narasimhan said that the company was researching treatments that deal with the secondary effects of […]

Read More
23andMe CEO Anne Wojcicki ‘surprised and disappointed’ by board resignations: Read the memo
Health

23andMe CEO Anne Wojcicki ‘surprised and disappointed’ by board resignations: Read the memo

Anne Wojcicki, co-founder and chief executive officer of 23andme Inc., during the South by Southwest (SXSW) festival in Austin, Texas, US, on Friday, March 10, 2023.  Jordan Vonderhaar | Bloomberg | Getty Images All seven independent directors of 23andMe resigned from the company’s board Tuesday, a move that CEO Anne Wojcicki said left her “surprised […]

Read More
Healthy Returns: How competitive can Roche be in the weight loss drug market?
Health

Healthy Returns: How competitive can Roche be in the weight loss drug market?

Headquarters of Roche, multinational pharmaceutical industry on December 27, 2021 in Madrid, Spain.  Cristina Arias | Cover | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon! Roche is one of several drugmakers […]

Read More